Reston, VA-Radionuclide therapy has proven successful in delaying the growth of disseminated tumor cells (DTCs) in early-stage breast cancer in a small animal model, suggesting its use as a potential adjuvant therapy for retarding the proliferation of DTCs. As reported in the January issue of The Journal of Nuclear Medicine, the alpha-particle-emitting radiopharmaceutical 223RaCl2 not only impacts cells directly hit by radiation, but also has significant effects on cells outside of the radiation field (i.e., bystander cells).

To read more please visit:

https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=33339

Source: The Society of Nuclear Medicine and Molecular Imaging